NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated. If, after doing this, organisations still wish to consider the use of carmustine implants for the treatment of recurrent glioblastoma multiforme, they should follow the advice set out in 'Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance' which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.
NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.
For information about NICE guidance that has been issued or is in development, see the website.
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. NICE technology appraisal guidance 121 (2007).
Improving outcomes for people with brain and other CNS tumours. NICE cancer service guidance (2006).
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer). NICE technology appraisal guidance 23 (2001).